{"product_id":"coo-ansoff-analysis","title":"(COO) The Cooper Companies, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Growth Paths Behind the Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis The Cooper Companies, Inc. Ansoff Matrix Analysis helps you quickly evaluate growth options across market penetration, market development, product development, and diversification in a concise framework; the page includes a real preview\/sample so you can judge style and depth before buying—purchase the full version to receive the complete, ready-to-use analysis for research, strategy, or investment work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmericas, EMEA, APAC lens share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn FY2025, The Cooper Companies, Inc. reported about $3.9 billion in net sales, with CooperVision near $2.8 billion, and its core lens lines already span the Americas, EMEA, and APAC. Market penetration here means taking more share in those same regions by expanding use of spherical, toric, and multifocal lenses across more eye-care accounts. Repeat replacement demand keeps the revenue stream sticky.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyopia, dry-eye, eye-fatigue mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCooperVision can sell its myopia, dry-eye, and eye-fatigue lenses into the same patient pool, so this is a straight market-share play in existing vision-correction markets. The logic is strong: myopia affects about 2.6 billion people worldwide, and dry eye affects around 344 million, giving CooperCompanies a large base for premium fits. In FY2025, CooperCompanies had about $3.9 billion in net sales, with CooperVision doing most of that work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePARAGARD provider retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePARAGARD retention is classic market penetration for CooperSurgical: keep PARAGARD in existing women’s-health and office-based provider channels, then lift use through repeat prescribing and easier reorders. PARAGARD is a hormone-free copper IUD with up to 10 years of pregnancy prevention and more than 99% effectiveness, so the value is in staying top of mind with current providers, not entering a new market. That makes share gains depend on utilization depth inside the same contraceptive channel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIVF consumables and embryo services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCooperSurgical’s IVF consumables, embryo services, and preimplantation genetic screening already sit inside the clinic workflow, so market penetration means taking a bigger share of spend from the same fertility lab base. That fits a repeat-buy model: once a clinic standardizes on one vendor, every cycle can lift consumables, equipment, and service revenue together.\u003c\/p\u003e\n\u003cp\u003eIn FY2024, The Cooper Companies reported $3.9 billion in net sales, with CooperSurgical contributing about $1.0 billion, so even a small share gain per clinic can move revenue meaningfully. The best win here is depth, not new geographies: more tests, more disposables, more embryo handling, and more switching cost.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSell more per clinic, not more clinics.\u003c\/li\u003e\n\u003cli\u003eBundle consumables with embryo services.\u003c\/li\u003e\n\u003cli\u003eRaise switching costs in existing labs.\u003c\/li\u003e\n\u003cli\u003eExpand wallet share in fertility accounts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUterine, retractor, closure bundle\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Cooper Companies, Inc. can push market penetration by bundling uterine manipulators, retractors, and closure devices into one surgical offer. The CooperSurgical unit already has these tools, so the move deepens share in the same hospital and office-based accounts and lifts cross-sell per case.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse one account, more products.\u003c\/li\u003e\n\u003cli\u003eSell deeper into existing surgical relationships.\u003c\/li\u003e\n\u003cli\u003eCooper Companies reported $3.9 billion in FY2024 net sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCooper’s FY2025 Sales Hit $3.9B on Recurring Lens Demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn FY2025, The Cooper Companies, Inc. generated about $3.9 billion in net sales, and CooperVision still drove most of that. Market penetration means selling more toric, multifocal, myopia, and dry-eye lenses to the same eye-care accounts and patients, where replacement demand stays recurring.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e$3.9 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCooperVision share\u003c\/td\u003e\n\u003ctd\u003eabout $2.8 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCooperSurgical share\u003c\/td\u003e\n\u003ctd\u003eabout $1.0 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing The Cooper Companies, Inc.’s growth strategy across products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix snapshot for The Cooper Companies, Inc., helping teams quickly align growth priorities across products and markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary Cooper Companies filings, investor presentations, market reports, and peer benchmarks to validate each Ansoff growth path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPAC lens expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCooperVision already sells spherical, toric, and multifocal lenses across Asia Pacific, so adding more country markets is market development, not product change. The move uses the same core lens line and the same fitting logic, which keeps rollout risk lower than a redesign. \u003c\/p\u003e\n\u003cp\u003eThe APAC contact lens market is still underpenetrated versus North America and Europe, so wider country coverage can lift volume without changing the product mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEMEA women’s-health rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn FY2025, CooperCompanies generated about $3.9 billion in revenue, and CooperSurgical can extend its same surgical, contraceptive, and fertility portfolio deeper into EMEA provider networks. The play is market development: the product set stays the same, but the customer base broadens across Europe, the Middle East, and Africa. That matters because EMEA already holds a large, fragmented women’s-health care market, so even small share gains can add meaningful recurring demand. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmericas fertility footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Cooper Companies' fertility platform can expand across the Americas by adding more clinics and labs, using its existing consumables, equipment, embryo services, and genetic screening. In FY2025, CooperSurgical stayed the company’s fertility engine, so this is a new-market move built on products already in use across the care cycle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal PGT access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCooperSurgical already sells preimplantation genetic screening as part of its fertility offer, so \"Global PGT access\" is market development: keep the same service and win more reproductive medicine centers. The Cooper Companies can grow by adding new accounts and clinic locations without changing the core test. In fiscal 2025, CooperSurgical remained a key driver of the group’s fertility platform.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame service, wider clinic reach\u003c\/li\u003e\n\u003cli\u003eTargets centers not yet using PGT\u003c\/li\u003e\n\u003cli\u003eScales via new accounts and sites\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdditional ophthalmic practice networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCooperVision can expand in market development by placing its same lens families, like MyDay, Biofinity, and clariti 1 day, into more optometry and ophthalmology networks in served regions. That matters because CooperCompanies generated about $4.0 billion in fiscal 2025 net sales, and even small wins in new practice groups can lift recurring lens volume. It is a market expansion move with existing products, not a product change.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSell into more practice networks.\u003c\/li\u003e\n\u003cli\u003eUse the same lens families.\u003c\/li\u003e\n\u003cli\u003eGrow in served regions.\u003c\/li\u003e\n\u003cli\u003eDrive recurring volume, not new SKUs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCooperCompanies Grows by Expanding Reach, Not Changing Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCooperCompanies’ market development is mainly about taking the same lens, fertility, and women’s-health products into more countries, clinics, and provider networks. In FY2025, net sales were about $3.9 billion, so even small share gains in new accounts can matter.\u003c\/p\u003e\n\u003cp\u003eCooperVision can widen reach in APAC and EMEA without changing MyDay, Biofinity, or clariti 1 day. CooperSurgical can do the same in fertility and surgical channels across the Americas and Europe.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eMarket move\u003c\/th\u003e\n\u003cth\u003eFY2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCooperVision\u003c\/td\u003e\n\u003ctd\u003eMore countries, same lenses\u003c\/td\u003e\n\u003ctd\u003e~$3.9B company sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCooperSurgical\u003c\/td\u003e\n\u003ctd\u003eMore clinics, same services\u003c\/td\u003e\n\u003ctd\u003eFertility remains key driver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eThe Cooper Companies, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-gen toric and multifocal lenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Cooper Companies, Inc. can use product development to upgrade CooperVision’s toric and multifocal lenses with better fit, comfort, and vision correction while keeping the same customer base. In FY2025, The Cooper Companies generated about $4.0 billion in revenue, and CooperVision remained its main growth engine. New lens designs can lift share in a market already served, without needing a new segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyopia and dry-eye updates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCooper Companies can keep pushing new versions of its myopia, dry-eye, and eye-fatigue lenses for the same users, which fits product development in Ansoff. Myopia already affects about 2.6 billion people worldwide, so even small wear-comfort gains can reach a huge base. Better moisture retention and optics can lift adherence and performance without leaving the contact lens market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFertility consumable upgrades\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCooperSurgical already serves fertility clinics, so new tools, disposables, and workflow upgrades fit product development, not market expansion. The Company reported about $3.9 billion in FY2024 net sales, and fertility care stays the same customer base while the kit gets more advanced. That means higher-value consumables can lift mix, margin, and repeat use without changing the core channel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroader PGT and testing panels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBroader PGT and testing panels fit The Cooper Companies, Inc. in product development because they expand existing genetic testing and preimplantation genetic screening tools into new versions with more markers, faster reads, or higher accuracy. In fiscal 2025, The Cooper Companies, Inc. reported about $4.0 billion in revenue, and CooperSurgical’s fertility franchise remains a key growth engine. Better panels can give fertility clinics more clinical decision support and improve embryo selection.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuild on existing PGT-A and screening tools.\u003c\/li\u003e\n\u003cli\u003eAdd speed, breadth, and accuracy.\u003c\/li\u003e\n\u003cli\u003eSupport clinic decisions with richer data.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew office-based surgical devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCooperSurgical can extend its office-based surgery line by iterating uterine manipulators, retractors, and closure tools for the same OB-GYN provider base, which is classic product development. In FY2025, The Cooper Companies reported about $4.0 billion in revenue, and CooperSurgical was roughly $1.4 billion, so even small mix gains in higher-margin adjacent devices can matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame customers, new devices\u003c\/li\u003e\n\u003cli\u003eDeepens gynecology workflow\u003c\/li\u003e\n\u003cli\u003eSupports office-based procedures\u003c\/li\u003e\n\u003cli\u003eBuilds on FY2025 scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCooper Companies: Better Lenses and Surgical Tools Drive Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProduct development at The Cooper Companies, Inc. means upgrading existing lenses and surgical tools for the same users. In FY2025, revenue was about $4.0 billion, with CooperVision as the main growth engine and CooperSurgical at about $1.4 billion. New toric, multifocal, PGT, and office-surgery designs can lift mix, comfort, and repeat use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eFY2025 scale\u003c\/th\u003e\n\u003cth\u003eProduct move\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCooperVision\u003c\/td\u003e\n\u003ctd\u003eAbout $2.6 billion\u003c\/td\u003e\n\u003ctd\u003eBetter lenses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCooperSurgical\u003c\/td\u003e\n\u003ctd\u003eAbout $1.4 billion\u003c\/td\u003e\n\u003ctd\u003eNew tools, PGT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2-unit eye care and women’s health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn fiscal 2025, The Cooper Companies, Inc. used two units, CooperVision and CooperSurgical, to span contact lenses plus women’s and family health. That mix puts it in two separate care markets, so demand is not tied to one product cycle. Diversification here means one company can balance steady vision care sales with more procedure-led health demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevices into fertility services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCooperSurgical pushes The Cooper Companies, Inc. beyond devices into fertility services, including embryo handling and preimplantation genetic screening. That shifts part of the mix from hardware to service-led reproductive medicine, with CooperSurgical generating about $1.1 billion of 2025 revenue. It is a broader, stickier market than contact lenses or surgery alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContraceptives, surgery, diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Cooper Companies, Inc. spans PARAGARD, surgical tools, diagnostics, and genetic testing, so its women’s health mix covers separate care paths and cuts reliance on one revenue stream. In fiscal 2025, the Company generated about $4.0 billion in revenue, showing the scale behind this diversified portfolio. That spread helps balance procedure demand, lab volumes, and contraceptive sales across related but different markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVision correction to reproductive medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCooperVision and CooperSurgical reach different buyers, with different cadences: contact lenses move through routine eye-care channels, while fertility and women’s health products sit in clinician-led, procedure-based care. That split gives The Cooper Companies, Inc. built-in diversification, with CooperVision still driving most revenue in FY2025 and CooperSurgical adding exposure to a separate healthcare market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDifferent end users\u003c\/li\u003e\n\u003cli\u003eDifferent buying cycles\u003c\/li\u003e\n\u003cli\u003eEye care plus fertility\u003c\/li\u003e\n\u003cli\u003eLower single-market risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal multi-region healthcare base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Cooper Companies, Inc. already spans the Americas, Europe, the Middle East, Africa, and Asia Pacific, so its healthcare demand is not tied to one region. Pairing that footprint with contact lenses, myopia care, and women’s health products widens diversification and softens cycle risk. That mix helps offset local slowdowns, pricing pressure, or reimbursement shifts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal reach lowers single-market risk\u003c\/li\u003e\n\u003cli\u003eMultiple products spread demand exposure\u003c\/li\u003e\n\u003cli\u003eBroader mix supports steadier growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwo Healthcare Engines Power Cooper’s Diversified Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversification in The Cooper Companies, Inc. rests on two distinct platforms: CooperVision and CooperSurgical. In fiscal 2025, revenue was about $4.0 billion, with CooperSurgical at about $1.1 billion, so the Company split exposure across routine vision care and procedure-led women’s health.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$4.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCooperSurgical revenue\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMix\u003c\/td\u003e\n\u003ctd\u003e2 healthcare markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191856996617,"sku":"coo-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/coo-ansoff-analysis.webp?v=1783678707","url":"https:\/\/dcfanalyst.com\/products\/coo-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}